Leading cancer organizations, partnering with the UK's National Health Service, are launching a groundbreaking trial to evaluate a cannabis-based oral spray for treating severe brain tumors.
Glioblastoma, a highly aggressive brain tumor originating from glial cells that support neuron function and nerve signaling, proliferates uncontrollably and infiltrates brain tissue. As the most malignant form of glioma, it carries a grim prognosis: patients typically survive less than 18 months post-diagnosis.
Standard treatment combines radiotherapy and chemotherapy, often following surgical resection. Now, in a pioneering clinical trial, experts are investigating a novel cannabis-derived oral spray as an adjunct therapy.
Preclinical studies on cell cultures and mouse models have indicated that cannabinoids can inhibit tumor growth when combined with temozolomide, a key chemotherapy agent. Building on this, human trials are underway.
Earlier this year, Professor Susan Short and her team at the University of Leeds completed a Phase I trial with 27 glioblastoma patients, assessing the safety of Sativex, an oral spray containing equal parts THC and CBD. Already approved for multiple sclerosis-related muscle spasms, Sativex demonstrated a compelling signal: 83% of participants receiving it survived one year, versus 44% on placebo.
The upcoming Phase II trial will enroll 232 patients across 15 UK hospitals. Two-thirds will receive Sativex alongside temozolomide; the rest, a placebo. Recruitment begins early 2022, funded by The Brain Tumour Charity, which seeks an additional £450,000 (about €526,000) to support the study.
Participants may self-administer up to 12 sprays daily for up to three years.
